TP53 is not a prognostic marker—clinical consequences of a generally disregarded fact

摘要: Technological progress within the last 15-20 years has significantly increased our knowledge about molecular basis of cancer development, tumor progression, and treatment response. As a consequence, vast number biomarkers have been proposed, but only small fraction them found their way into clinical use. The aim this paper is to describe specific demands clinically relevant biomarker should meet how can be tested stepwise. We name procedure "triple-R principle": robustness, reproducibility, relevance. usefulness principle illustrated with marker TP53. Since it mutated in broad spectrum entities, TP53 considered very promising marker. Thus, studied detail there still no explicit consensus its value. By considering own experience reviewing literature, we demonstrate that major problem current research disregard whether prognostic or predictive. an example, demonstrated not marker, rather purely predictive fact made otherwise strong appear as being useful so far.